
    
      This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to
      evaluate the efficacy, safety, and tolerability of ANB019 compared with placebo in adolescent
      and adult subjects with ichthyosis. This study will also characterize the pharmacokinetic
      (PK) profile of ANB019 and explore the immune response to ANB019 in subjects with ichthyosis.
    
  